Implementación y optimización del proceso sintético de i) complejos aminoácido - estaño IV y ii) péptidos conjugados con Ferroceno, como contribución al desarrollo de fármacos basados en moléculas organometálicas
Cancer is a global public health problem that is significantly affecting the Colombian population. Despite the advances made in the development and / or improvement of treatments, the morbidity / mortality rates are continuously increasing. To date, great efforts have been made to identify new thera...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis de maestría |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2020 |
| País: | Colombia |
| Institución: | Universidad Nacional de Colombia |
| Repositorio: | Repositorio UN |
| Idioma: | español |
| OAI Identifier: | oai:repositorio.unal.edu.co:unal/79171 |
| Acceso en línea: | https://repositorio.unal.edu.co/handle/unal/79171 |
| Access Level: | acceso abierto |
| Palabra clave: | Organotin IV Ferrocene Conjugated Aminoacids Organometallic Peptide Synthesis of drugs Organoestaño IV Ferroceno Aminoácidos Conjugados Péptidos Organometálicos Síntesis de Fármacos |
| Sumario: | Cancer is a global public health problem that is significantly affecting the Colombian population. Despite the advances made in the development and / or improvement of treatments, the morbidity / mortality rates are continuously increasing. To date, great efforts have been made to identify new therapeutic approaches, with organometallic peptides (POM) -based drugs being a promising alternative. These POMs are an anticancer peptide into which a metallocene is incorporated. These molecules have presented great biological potential for the development of anticancer agents, since they combine the cytotoxic activity of the organometallic motif (OM) and the peptide, in addition to the metallocene, they give stability to the drug in biological environments. In this work, I) organotin IV compounds were designed, purified and characterized from polar amino acids (Asp, Lys and Glu), some of which have not been reported in the consulted literature, in addition an organometallic block was synthesized which It can be used for the synthesis of organotin IV conjugated POMs. (ii) the synthetic route was optimized to obtain peptides and POMs containing Ferrocene, derived from the palindromic sequence RWQWRWQWR. In this work, synthetic routes were designed and the procedures for obtaining POMs conjugated with Ferrocene or Organotin IV were implemented. Our results suggest that obtaining peptides and / or amino acids conjugated with organometallic compounds is viable, therefore, they can be considered for the development of new therapeutic agents against cancer. |
|---|